- Home
- CCCC vs SKYE Comparison
CCCC vs SKYE Comparison
Compare CCCC & SKYE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CCCC
- SKYE
- Stock Information
- Founded
- CCCC 2015
- SKYE 2012
- Country
- CCCC United States
- SKYE United States
- Employees
- CCCC N/A
- SKYE N/A
- Industry
- CCCC Biotechnology: Pharmaceutical Preparations
- SKYE Biotechnology: Pharmaceutical Preparations
- Sector
- CCCC Health Care
- SKYE Health Care
- Exchange
- CCCC Nasdaq
- SKYE Nasdaq
- Market Cap
- CCCC 405.6M
- SKYE 108.3M
- IPO Year
- CCCC 2020
- SKYE N/A
- Fundamental
- Price
- CCCC $6.25
- SKYE $4.78
- Analyst Decision
- CCCC Buy
- SKYE Buy
- Analyst Count
- CCCC 6
- SKYE 6
- Target Price
- CCCC $10.50
- SKYE $18.67
- AVG Volume (30 Days)
- CCCC 731.1K
- SKYE 330.3K
- Earning Date
- CCCC 10-30-2024
- SKYE 11-09-2024
- Dividend Yield
- CCCC N/A
- SKYE N/A
- EPS Growth
- CCCC N/A
- SKYE N/A
- EPS
- CCCC N/A
- SKYE N/A
- Revenue
- CCCC $29,378,000.00
- SKYE N/A
- Revenue This Year
- CCCC $39.70
- SKYE N/A
- Revenue Next Year
- CCCC N/A
- SKYE N/A
- P/E Ratio
- CCCC N/A
- SKYE N/A
- Revenue Growth
- CCCC 83.26
- SKYE N/A
- 52 Week Low
- CCCC $1.06
- SKYE $1.44
- 52 Week High
- CCCC $11.88
- SKYE $19.41
- Technical
- Relative Strength Index (RSI)
- CCCC 54.57
- SKYE 53.92
- Support Level
- CCCC $6.26
- SKYE $3.53
- Resistance Level
- CCCC $7.14
- SKYE $4.53
- Average True Range (ATR)
- CCCC 0.37
- SKYE 0.41
- MACD
- CCCC 0.12
- SKYE 0.15
- Stochastic Oscillator
- CCCC 58.99
- SKYE 100.00
About CCCC C4 Therapeutics Inc.
C4 Therapeutics Inc is a biopharmaceutical company advancing targeted protein degradation science to develop a new generation of small-molecular medicines to transform how the disease is treated. Its TORPEDO platform enables the discovery of a new class of targeted investigational small-molecule medicines called protein degraders.
About SKYE Skye Bioscience Inc. Common Stock
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.